Laboratory of Precision Preventive Medicine, School of Basic Medicine, Jiujiang University, Jiujiang, China.
Jiangxi Provincial Key Laboratory of Cell Precision Therapy, School of Basic Medical Sciences, Jiujiang University, China.
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241245939. doi: 10.1177/15330338241245939.
Small nucleolar RNAs (snoRNAs) form clusters within the genome, representing a mysterious category of small non-coding RNAs. Research has demonstrated that aberrant snoRNAs can contribute to the development of various types of cancers. Recent studies have identified snoRNAs as potentially valuable biomarkers for the diagnosis or/and prognosis of cancers. However, there has been a lack of comprehensive reviews on prognostic and diagnostic snoRNAs across different types of cancers.
We conducted a systematic search of various databases including Google Scholar, Medline, Cochrane, Scopus, PubMed, Embase, ScienceDirect, Ovid-Medline, Chinese National Knowledge Infrastructure, WanFang, and SinoMed with a time frame reception to December 30, 2022. A total of 49 relevant articles were included in our analysis, consisting of 21 articles focusing on diagnostic aspects and 41 articles focusing on prognostic aspects. Pooled odds ratio, 95% confidence intervals (CIs), and hazard ratio (HR) were utilized to evaluate clinical parameters and overall survival (OS), respectively.
The findings indicated that area under the curve, sensitivity, and specificity were 0.85, 75%, and 80% in cancer, respectively. There was a possibility that snoRNAs had a positive impact on the diagnosis (risk ratio, RR = 2.95, 95% CI: 2.75-3.16, = 0.000) and OS (HR = 1) in cancer. Additionally, abnormally expressed snoRNAs were associated with a positive impact on OS time for chronic lymphocytic leukemia (HR: 0.88, 95%Cl: 0.69-1.11, < 0.00001), colon adenocarcinoma (HR: 0.97, 95%Cl: 0.91-1.03, < 0.0001), and ovarian cancer (HR: 0.98, 95%Cl: 0.98-0.99, < 0.00001). However, dysregulated snoRNAs of colon cancer and colorectal cancer had a negative impact on OS time (HR = 3.01 and 1.01 respectively, < 0.0001).
The results strongly suggested that snoRNAs could serve as potential novel indicators for prognosis and diagnosis in cancers. This systematic review followed the guidelines of the Transparent Reporting of Systematic Review and Meta-Analyses (PROSPERO register: CRD42020209096).
小核仁 RNA（snoRNA）在基因组内形成簇，代表一类神秘的非编码小 RNA。研究表明，异常 snoRNA 可能导致多种类型的癌症的发生。最近的研究表明，snoRNA 可能是癌症诊断或/和预后的有价值的生物标志物。然而，对于不同类型癌症中的预后和诊断 snoRNA ，缺乏全面的综述。
我们系统地检索了各种数据库，包括 Google Scholar、Medline、Cochrane、Scopus、PubMed、Embase、ScienceDirect、Ovid-Medline、中国知网、万方和中国生物医学文献数据库，检索时间截至 2022 年 12 月 30 日。共有 49 篇相关文章纳入我们的分析，其中 21 篇文章侧重于诊断方面，41 篇文章侧重于预后方面。采用合并优势比（OR）、95%置信区间（CI）和风险比（HR）分别评估临床参数和总生存期（OS）。
结果表明，癌症中的曲线下面积、敏感度和特异度分别为 0.85、75%和 80%。snoRNA 对癌症的诊断（风险比，RR=2.95，95%CI：2.75-3.16，=0.000）和 OS（HR=1）可能有积极影响。此外，异常表达的 snoRNA 与慢性淋巴细胞白血病（HR：0.88，95%CI：0.69-1.11，<0.00001）、结肠腺癌（HR：0.97，95%CI：0.91-1.03，<0.0001）和卵巢癌（HR：0.98，95%CI：0.98-0.99，<0.00001）的 OS 时间呈正相关。然而，结肠癌和结直肠癌的失调 snoRNA 对 OS 时间有负面影响（HR=3.01 和 1.01，均<0.0001）。
研究结果强烈表明 snoRNA 可能成为癌症预后和诊断的潜在新型标志物。本系统综述遵循系统评价和荟萃分析的透明报告（PROSPERO 登记号：CRD42020209096）的指南。
